Article in Cold Spring Harbor molecular case studies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 6 institutions in 2 countries.
Meghan R Sullivan *Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA.ORCID 0000-0002-0814-6755
Rohit Prakash *Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.ORCID 0000-0001-5981-8980
Yashpal Rawal *Department of Biochemistry and Structural Biology, UT Health Science Center at San Antonio, San Antonio, Texas 78229, USA.ORCID 0000-0001-9209-788X
Weibin WangDepartment of Radiation Medicine, Peking University Health Science Center, Beijing, 100191, China.ORCID 0000-0003-3087-7973
Patrick SungDepartment of Biochemistry and Structural Biology, UT Health Science Center at San Antonio, San Antonio, Texas 78229, USA.ORCID 0000-0003-1396-9040
Marc R RadkeDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195, USA.ORCID 0000-0003-0983-7838
Scott H KaufmannDepartments of Oncology and Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA.ORCID 0000-0002-4900-7145
Elizabeth M SwisherDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195, USA.ORCID 0000-0003-2331-0434
Kara A BernsteinDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA.ORCID 0000-0003-2247-6459
Maria JasinDevelopmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.ORCID 0000-0002-7976-2379
Memorial Sloan Kettering Cancer Center · USThe University of Texas Health Science Center at San Antonio · USUniversity of Pittsburgh · USUniversity of Washington · USMayo Clinic · USPeking University · CN
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
YEAST DNA REPAIR GENES AND PROTEINS OF THE RAD52 GROUPR01ES007061 · NIEHS · YALE UNIVERSITY · PI Patrick Sung · 1995 to 2026
$9.4M
Homology-directed repair: BRCA2 and RAD51 paralogsR35CA253174 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Maria Jasin · 2020 to 2026
$6.7M
Mechanisms of DNA Homology-directed Genome Repair and Tumor SuppressionR35CA241801 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SUNG, PATRICK · 2019 to 2025
$6.0M
Replication fork dynamics and repair by Rad51 paralogues after DNA alkylationR01ES030335 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Kara A Bernstein · 2019 to 2026
$2.9M
HOMOLOGY-DIRECTED DNA REPAIR PROTEINS BRCA2 AND RAD51 PARALOGS IN TUMOR-RELEVANT TISSUESR01CA185660 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JASIN, MARIA · 2014 to 2020
$2.7M
RAD51 paralog function in cancer predisposition and genome integrity R01ES031796 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BERNSTEIN, KARA A · 2021 to 2025
$2.2M
The interplay between RAD51C sub-complexes during replication fork repairF31ES027321 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SULLIVAN, MEGHAN · 2017 to 2018
Mutations in homologous recombination (HR) genes predispose to cancer but also sensitize to chemotherapeutics. Although therapy can initially be effective, cancers frequently cease responding, leading to recurrence and poor prognosis. Here we identify a germline mutation in
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation. · full record | OpenQuestion